Christopher R. M. Asquith

Dr. Christopher R. M. Asquith

Department of Pharmacology, School of Medicine, University of North Carolina at Chapel Hill, NC 27599, USA
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
CWCarrow Wells
Carrow Wells
HAHassan Al-Ali
Hassan Al-Ali
DADavid Andrews
David Andrews
CAChristopher R. M. Asquith
Christopher R. M. Asquith
Alison Donnelly AxtmanAlison Donnelly Axtman
Alison Donnelly Axtman
David DrewryDavid Drewry
David Drewry
We describe the assembly and annotation of a chemogenomic set of protein kinase inhibitors as an open science resource for studying kinase biology. The set only includes inhibitors that show potent kinase inhibition and a narrow spectrum of activity when screened across a large panel of kinase biochemical assays. Currently, the set contains 187 inhibitors that cover 215 human kinases. The kinase chemogenomic set (KCGS), current Version 1.0, is the most highly annotated set of selective kinase inhibitors available to researchers for use in cell-based screens.

15 February 2019 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CAChristopher R. M. Asquith
Christopher R. M. Asquith
Benedict-Tilman BergerBenedict-Tilman Berger
Benedict-Tilman Berger
JWJing Wan
Jing Wan
JBJames M. Bennett
James M. Bennett
SCStephen Capuzzi
Stephen Capuzzi
WZWilliam Zuercher
William Zuercher

26 October 2017 in ChemMedChem
Verified
Journal Article
Open access
PDF file
CAChristopher R. M. Asquith
Christopher R. M. Asquith
TLTuomo Laitinen
Tuomo Laitinen
JBJames M. Bennett
James M. Bennett
PGPaulo H. Godoi
Paulo H. Godoi
MEMichael P. East
Michael P. East
WZWilliam Zuercher
William Zuercher
4‐Anilinoquinolines were identified as potent and narrow‐spectrum inhibitors of the cyclin G associated kinase (GAK), an important regulator of viral and bacterial entry into host cells. Optimization of the 4‐anilino group and the 6,7‐quinoline substituents produced GAK inhibitors with nanomolar activity, over 50 000‐fold selectivity relative to other members of the numb‐associated kinase (NAK) subfamily, and a compound (6,7‐dimethoxy‐N‐(3,4,5‐trimethoxyphenyl)quinolin‐4‐amine; 49) with a narrow‐spectrum kinome profile. These compounds may be useful tools to explore the therapeutic potential of GAK in prevention of a broad range of infectious and systemic diseases.

8 August 2017 in Journal of Chemical Education
Verified
Journal Article
Closed access
MPMatthew R. Penny
Matthew R. Penny
ZCZi Jing Cao
Zi Jing Cao
Bhaven PatelBhaven Patel
Bhaven Patel
BSBruno Santos
Bruno Santos
CAChristopher R. M. Asquith
Christopher R. M. Asquith
SHStephen Timothy Hilton
Stephen Timothy Hilton

15 July 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
BEBenjamin J. Eduful
Benjamin J. Eduful
SOSean N. O’bYrne
Sean N. O’bYrne
LTLouisa Temme
Louisa Temme
CAChristopher R. M. Asquith
Christopher R. M. Asquith
YLYi Liang
Yi Liang
David DrewryDavid Drewry
David Drewry
CAMKK2 is a serine/threonine kinase and an activator of AMPK whose dysregulation is linked with multiple diseases. Unfortunately, STO-609, the tool inhibitor commonly used to probe CAMKK2 signaling, has limitations. To identify promising scaffolds as starting points for the development of high-quality CAMKK2 chemical probes, we utilized a hinge-binding scaffold hopping strategy to design new CAMKK2 inhibitors. Starting from the potent but promiscuous disubstituted 7-azaindole GSK650934, a total of 32 compounds, composed of single-ring, 5,6-, and 6,6-fused heteroaromatic cores, were synthesized. The compound set was specifically designed to probe interactions with the kinase hinge-binding residues. Compared to GSK650394 and STO-609, 13 compounds displayed similar or better CAMKK2 inhibitory potency in vitro, while compounds 13g and 45 had improved selectivity for CAMKK2 across the kinome. Our systematic survey of hinge-binding chemotypes identified several potent and selective inhibitors of CAMKK2 to serve as starting points for medicinal chemistry programs.

1 July 2019 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
CAChristopher R. M. Asquith
Christopher R. M. Asquith
TMTheres Meili
Theres Meili
TLTuomo Laitinen
Tuomo Laitinen
IBIlia V. Baranovsky
Ilia V. Baranovsky
LKLidia S. Konstantinova
Lidia S. Konstantinova
Regina Hofmann-LehmannRegina Hofmann-Lehmann
Regina Hofmann-Lehmann